C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
13 nov. 2020 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys...
C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
12 nov. 2020 16h05 HE
|
C4 Therapeutics, Inc.
– Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer – – Completed upsized...
C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit
14 oct. 2020 07h30 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
06 oct. 2020 16h05 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...
C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering
01 oct. 2020 21h58 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...